Medicane Health

Company Overview

Snapshot

Founded in January 2019 by Yossi Ben Amram and Hagai Greenspoon, Medicane Health operates with 11–50 employees. The company recently achieved a significant milestone by receiving an EU GMP License for its manufacturing plant in Portugal in February 2022, underscoring its commitment to pharmaceutical-grade production.

Business overview

Medicane Health is an international pharmaceutical company focused on the research, development, production, and marketing of cannabis-based medications. The company develops products through both medical cannabis and pharmaceutical regulatory pathways, utilizing whole plant extractions and isolated ingredients. It serves European markets that support medical cannabis legislation, aiming to advance medical research and provide symptom relief for patients whose needs are not met by traditional treatments. Medicane Health operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Cannabis.

Strategic signal

In October 2022, Medicane Health announced the enrollment of the first patient in a Phase IIa clinical trial for its Balanced T3:C3 Oral Medical Cannabis Oil, targeting the relief of Behavioral and Psychological Symptoms of Dementia (BPSD). This development signals the company's progress in clinical research and its commitment to validating cannabis-based therapies for specific medical conditions, which could significantly impact the pharmaceutical and medical cannabis markets.

Company Intelligence Q&A

What is Medicane Health's primary focus?

Medicane Health is an international pharmaceutical company engaged in the research, development, production, and marketing of cannabis-based medications, focusing on European countries that promote legislation for medical cannabis.

When did Medicane Health receive its EU GMP License for its Portugal plant?

In February 2022, Medicane Health Inc. received an EU GMP License for its manufacturing plant in Portugal, enabling it to produce pharmaceutical-grade products.

What clinical trial did Medicane Health announce in October 2022?

In October 2022, Medicane Health announced the enrollment of the first patient in a Phase IIa clinical trial for its Balanced T3:C3 Oral Medical Cannabis Oil, aimed at relieving Behavioral and Psychological Symptoms of Dementia (BPSD).

What strategic partnership did Medicane Health announce in April 2022?

In April 2022, Dr. Reddy's Laboratories and MediCane Health announced the launch of medical cannabis products in Germany, indicating a strategic market entry and partnership.

When was the first social media platform for cannabis patients launched by Medicane Health?

In July 2021, Medicane Health launched the first social media platform specifically for cannabis patients, aiming to create a community and support network.